| Ytd | 19.47% | |
| 1y | -3.57% |
| Open | 1.38 | Prev Close | 1.38 | Low | 1.33 | High | 1.40 | Mkt Cap | 31.03M |
| Vol | 174.05K | Avg Vol | 908.84K | EPS | -0.44 | P/E | N/A | Forward P/E | -2.68 |
| Beta | 0.97 | Short Ratio | 1.92 | Inst. Own | 9.42% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-15 | 50-d Avg | 1.44 | 200-d Avg | 1.29 | 1yr Est | 6.50 |
NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a c
SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE
Clinical Trial Site preparations are being performed by our CRO in India, Om Sai Clinical Research P
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), a clinical stage leader developing antivira
NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing
https://www.sec.gov/Archives/edgar/data/1379006/000110465926071007/tm2616485d1_s3.htm